Study | Design | Type of LMWH | No. Patients | Non-Fatal Bleeding | Fatal Bleeding |
---|---|---|---|---|---|
Geerts et al. 1996[10] | Randomized | Â | Â | Â | Â |
 | UH 5,000 U SC BID vs. LMWH 30 mg SC BID | Enoxaparin | 171* | 5 (2.9%) | 0 |
 | Multi-system trauma & ISS ≥ 9 |  |  |  |  |
Knudson et al. 1996[20] | Randomized | Â | Â | Â | Â |
 | LMWH 30 mg SC BID vs. SCD or AVI bilaterally | Enoxaparin | 120 | 6 (5%) | 0 |
 | Multi-system trauma & AIS ≥ 3 with ISS > 10 |  |  |  |  |
Ginzburg et al. 2003[19] | Randomized | Â | Â | Â | Â |
 | LMWH 30 mg BID vs. IPC bilaterally | Enoxaparin | 218 | 13 (6%) | 0 |
 | Multi-system trauma & ISS ≥ 9 |  |  |  |  |
 | Multi-system Trauma Bleeding Risk | 24/509 (4.7%) | 0% | ||
Green et al. 1990[17] | Randomized | Â | Â | Â | Â |
 | UH 5,000 U SC TID vs. LMWH 3500 U SC QD | Logiparin | 20 | 0 | 0 |
 | Spinal cord trauma & complete motor paraylsis |  |  |  |  |
Spinal Cord Injury Thromboprophylaxis Investigators 2003[18] | Randomized | Â | Â | Â | Â |
 | UH 5,000 U SC TID + IPC vs. LMWH 30 mg SC BID | Enoxaparin | 230 | 6 (2.6%) | 0 |
 | Spinal cord trauma |  |  |  |  |
Kurtoglu et al. 2004[13] | Randomized | Â | Â | Â | Â |
 | LMWH 40 mg QD vs. IPC bilaterally | Enoxaparin | 60 | 2 (3.3%) | 0 |
 | Head and Spinal Trauma |  |  |  |  |
 | Spinal Cord Trauma Bleeding Risk | 8/310 (2.6%) | 0% | ||
 | Combined Total Bleeding Risk | 32/819 (3.9%) | 0% |